- Home
- OSRH vs TOVX Comparison
OSRH vs TOVX Comparison
Compare OSRH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OSRH | TOVX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 14.7M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | OSRH | TOVX |
|---|---|---|
| Price | $0.38 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 928.1K | ★ 12.4M |
| Earning Date | 05-19-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.30 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.16 |
| 52 Week High | $1.57 | $0.86 |
Technical Indicators
Market Signals| Indicator | OSRH | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 41.03 |
| Support Level | N/A | $0.18 |
| Resistance Level | $0.45 | $0.28 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 10.64 | 12.49 |
Price Performance
Historical ComparisonAbout OSRH OSR Holdings Inc.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea. The company's pipeline products include: Vaximm, Darnatein, Woori IO, and RMC.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.